⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 15, 2015JAMA OncologyOpen Access

Balancing Benefit, Risk, and Time to New Cancer Therapies

View Full Paper

Ask AI

Bookmark

Share

Abstract

immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Howard West (2015) studied this question.

synapsesocial.com/papers/6ab1fc8460df2b73ab437266 https://doi.org/10.1001/jamaoncol.2015.4126

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast CancerJAMA Oncology · Thu,
2“Low-Risk” Ovarian Lesions—The Case for Early Follow-UpJAMA Oncology · Thu,
3Long-Term Outcomes of De-Escalated 30-Gy Elective Irradiation in HPV-Associated Oropharyngeal CancerJAMA Oncology · Thu,
4Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell CarcinomaJAMA Oncology · Thu,
5Nivolumab-Ipilimumab for Localized Microsatellite Instability–High Gastric/Gastroesophageal Junction AdenocarcinomaJAMA Oncology · Thu,

More from JAMA Oncology

Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECISTThu,
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2 -Positive, Non–Muscle-Invasive Bladder CancerThu,
Rethinking Treatment Intensification in Poorly Chemosensitive Ovarian CancerThu,
Immune Checkpoint Inhibitor–Based Downstaging Therapy for Hepatocellular CarcinomaThu,
Rethinking Value in Cancer Care in the USThu,